Report on Pacritinib (VONJO™): A Comprehensive Monograph

Executive Summary and Drug Profile

Overview

Pacritinib is an orally bioavailable, small molecule multi-kinase inhibitor developed for the treatment of myelofibrosis (MF), a life-threatening bone marrow disorder.[1] Pharmacologically, it is classified as an inhibitor of Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), targeting key signaling pathways implicated in the pathogenesis of myeloproliferative neoplasms.[4] Marketed in the United States under the brand name VONJO™, pacritinib represents a significant therapeutic advancement, particularly for a subset of patients with limited treatment options.[6] It is identified by DrugBank ID DB11697 and CAS Number 937272-79-2.[8]

Core Indication and Clinical Niche

Pacritinib occupies a unique and critical position in the clinical armamentarium as the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis who present with severe thrombocytopenia, specifically a platelet count below 50×109/L.[9] This specific indication addresses a profound unmet medical need, as other approved JAK inhibitors, such as ruxolitinib and fedratinib, are often associated with myelosuppressive effects that can exacerbate or induce thrombocytopenia, thereby limiting their use or requiring dose interruptions in this vulnerable patient population.[12]

Efficacy and Safety Synopsis

The regulatory approval of pacritinib was granted under the FDA's accelerated approval pathway, based on its demonstrated ability to achieve a statistically significant reduction in spleen volume (SVR), a well-established surrogate endpoint for clinical benefit in myelofibrosis.[9] However, the therapeutic benefits of pacritinib are balanced by a complex safety profile. Common adverse events include gastrointestinal toxicities such as diarrhea and nausea, as well as hematologic effects like anemia and worsening thrombocytopenia.[4] More seriously, the drug's label includes warnings for hemorrhage, prolongation of the QTc interval, and class-wide risks for major adverse cardiovascular events (MACE), venous and arterial thrombosis, and the development of secondary malignancies.[1]

Regulatory Narrative

The developmental and regulatory history of pacritinib is notable for its significant challenges and ultimate perseverance. The program faced a full clinical hold by the FDA due to safety concerns that emerged from interim trial analyses, including an apparent increase in mortality and bleeding events.[12] These same concerns contributed to the withdrawal of its marketing authorization application from the European Medicines Agency (EMA), which deemed the risk-benefit profile unfavorable based on the data presented.[17] The eventual accelerated approval in the United States for a narrowly defined, high-need patient population reflects a meticulous re-evaluation of the data, particularly focusing on a specific dose, and a regulatory judgment that the benefits in this desperate cohort outweighed the identified risks. This outcome stands in stark contrast to the more cautious position adopted by European regulators, highlighting differing philosophies on risk tolerance and the definition of unmet medical need.

Physicochemical Properties and Formulation

Identification and Nomenclature

Pacritinib is systematically identified through a variety of chemical and regulatory naming conventions.

• Generic Name: Pacritinib [4]
• Brand Name: VONJO™ [4]
• Synonyms/Developmental Codes: SB1518 [2]
• IUPAC Name: (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo$[19.3.1.1^{2,6}.1^{8,12}]$heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene [8]
• Key Identifiers:
• DrugBank ID: DB11697 [8]
• CAS Number: 937272-79-2 [2]
• KEGG ID: D11768 [8]

Molecular and Physical Characteristics

Pacritinib possesses a distinct molecular structure and set of physical properties that define its behavior as a pharmaceutical agent.

• Chemical Class: It is classified as an azamacrocycle and a member of the pyrrolidine family. Its unique macrocyclic (4-aryl-2-aminopyrimidine) structure is a key design feature, categorizing it as a bridged-ring compound.[8]
• Molecular Formula: C28​H32​N4​O3​ [2]
• Molecular Weight: The molecular weight is consistently reported to be approximately 472.58 to 472.6 g/mol.[2]
• Physical Appearance: In its pure form, pacritinib is a crystalline solid, described as light yellow to yellow in color.[20]
• Solubility: It exhibits poor solubility in aqueous media, being insoluble in water and ethanol. It is soluble in dimethyl sulfoxide (DMSO), particularly with the application of gentle warming.[20]

The fundamental physicochemical properties of pacritinib are summarized in Table 2.1.

Table 2.1: Summary of Physicochemical Properties of Pacritinib

Property	Value	Source(s)
Generic Name	Pacritinib	4
Brand Name	VONJO™	4
CAS Number	937272-79-2	2
DrugBank ID	DB11697	8
Molecular Formula	C28​H32​N4​O3​	8
Molecular Weight	472.59 g/mol	26
IUPAC Name	(16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo$[19.3.1.1^{2,6}.1^{8,12}]$heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene	8
Chemical Class	Azamacrocycle, Pyrrolidine, Bridged-Ring Compound	8
Physical Appearance	Crystalline Solid	20
Solubility	Insoluble in water; Soluble in DMSO with warming	20

Commercial Formulation

Pacritinib is commercially formulated and supplied as VONJO™ 100 mg capsules intended for oral administration.[4]

Comprehensive Pharmacological Profile

Mechanism of Action: Inhibition of the JAK-STAT Pathway

Pacritinib belongs to the class of medications known as kinase inhibitors. Its fundamental mechanism of action involves blocking the function of abnormal proteins that transmit signals for cancer cells to multiply, thereby helping to slow or stop the proliferation of malignant cells.[30] The primary therapeutic effect of pacritinib in myelofibrosis is achieved through the targeted inhibition of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway.[3]

The pathogenesis of myelofibrosis is frequently driven by somatic mutations in the JAK2 gene, with the activating JAK2V617F mutation being the most prevalent, occurring in approximately 50% of patients with primary MF and a majority of those with post-polycythemia vera or post-essential thrombocythemia MF.[8] This gain-of-function mutation results in constitutive, cytokine-independent activation of the JAK-STAT pathway. This aberrant signaling cascade drives the key features of the disease, including uncontrolled proliferation of hematopoietic cells, excessive production of inflammatory cytokines, and the progressive replacement of bone marrow with scar tissue (fibrosis).[4] Pacritinib directly intervenes in this process by inhibiting JAK2, which in turn prevents the downstream phosphorylation and activation of STAT proteins, such as STAT3 and STAT5. This action effectively interrupts the pathogenic signaling responsible for the disease phenotype.[3]

Primary Kinase Targets: JAK2 and FLT3

Pacritinib is characterized by its potent and equipotent inhibitory activity against both wild-type JAK2 and its key pathogenic mutant, JAK2V617F. In vitro assays have demonstrated half-maximal inhibitory concentrations (IC50​) of 23 nM for wild-type JAK2 and 19 nM for the JAK2V617F mutant.[2]

In addition to its activity against JAK2, pacritinib is also a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), another critical receptor tyrosine kinase involved in hematopoiesis. It effectively inhibits both wild-type FLT3 (IC50​=22 nM) and its common activating mutants, such as FLT3 with internal tandem duplications (FLT3-ITD) and the FLT3D835Y mutation (IC50​=6 nM).[2] This dual JAK2/FLT3 inhibition is a distinguishing feature of the drug. While JAK2 is the primary target in myelofibrosis, FLT3 mutations are the most frequent genetic alterations in acute myeloid leukemia (AML) and are associated with a poor prognosis.[33] This dual activity suggests a broader potential therapeutic utility for pacritinib in other hematologic malignancies, and preclinical models of FLT3-ITD-driven AML have shown that oral administration of pacritinib can significantly inhibit tumor growth and metastasis.[3]

Kinome Selectivity and Secondary Targets

The therapeutic profile of pacritinib is further defined by its selectivity within the broader kinome, particularly within the JAK family itself.

• JAK Family Selectivity: A critical pharmacological attribute of pacritinib is its relative specificity for JAK2 over other JAK family members. While it potently inhibits JAK2, it exhibits significantly less activity against JAK3 (IC50​=520 nM) and TYK2 (IC50​=50 nM). Most importantly, pacritinib does not inhibit JAK1 at clinically relevant concentrations (IC50​=1280 nM).[5] This JAK1-sparing profile is the cornerstone of its clinical utility in patients with cytopenias. The signaling pathways mediated by JAK1 are essential for normal hematopoiesis and immune function. By selectively inhibiting the primary disease driver (JAK2) while preserving JAK1-mediated signaling, pacritinib can exert its therapeutic effect with a reduced propensity for the myelosuppression (anemia and thrombocytopenia) that is often a dose-limiting toxicity for less selective JAK1/2 inhibitors.[25] This pharmacological differentiation provides a clear scientific rationale for its unique indication in patients with severe thrombocytopenia, a population that cannot tolerate the myelosuppressive effects of other agents.
• Other Relevant Targets: Comprehensive kinome screening has revealed that pacritinib also inhibits other kinases at low nanomolar concentrations. These include interleukin-1 receptor-associated kinase 1 (IRAK1) and colony-stimulating factor 1 receptor (CSF1R).[2] The inhibition of these targets, which are involved in inflammatory signaling, may contribute to pacritinib's overall clinical effect by reducing the production of hematopoietic inhibitory cytokines and further mitigating the inflammatory state characteristic of myelofibrosis.[33]

Pharmacokinetics and Metabolism (ADME)

Absorption

Pacritinib is designed for oral administration and demonstrates good bioavailability. Preclinical studies in animal models have shown oral bioavailability values of 39% in mice, 10% in rats, and 24% in dogs.[3] In humans, following single oral doses ranging from 100 to 400 mg, the systemic exposure (as measured by AUC) increases in a linear but less than dose-proportional manner.[37] A key clinical advantage is that the absorption of pacritinib is not significantly affected by food intake, allowing for flexible administration with or without meals.[1]

Distribution

Pacritinib is widely distributed throughout the body, as indicated by a high volume of distribution in preclinical species (e.g., 14.2 L/kg in mice).[24] A significant pharmacokinetic characteristic is its very high binding to human plasma proteins. This extensive protein binding is thought to contribute to its relatively high plasma concentrations and long elimination half-life in humans.[24] Preclinical whole-body autoradiography studies have shown that while radioactivity is concentrated in the gastrointestinal tract, kidney, and heart, there is low penetration into the brain, suggesting limited passage across the blood-brain barrier.[2]

Metabolism

Pacritinib undergoes hepatic metabolism, with the cytochrome P450 3A4 (CYP3A4) enzyme serving as the primary metabolic pathway.[4] In vitro and in vivo studies have identified four major metabolites, designated M1, M2, M3, and M4, which are formed through processes of oxidation, dealkylation, and reduction.[24] However, these metabolites are considered to have low pharmacological potency and are unlikely to contribute meaningfully to the drug's clinical activity. The parent pacritinib compound is the predominant active moiety circulating in the plasma.[37] Pacritinib itself does not significantly induce CYP3A or CYP1A2 enzymes in human hepatocytes.[24]

Excretion

The primary route of elimination for pacritinib and its metabolites is via the feces, which strongly suggests that biliary clearance is the main excretory pathway. In a radiolabeled mass balance study conducted in mice, approximately 91% of the administered dose was recovered in the feces, while only a small fraction (~3.2%) was recovered in the urine.[24] In human subjects, pacritinib exhibits a long mean terminal elimination half-life of approximately 43 hours after a single dose.[37]

Drug-Drug Interactions

The pharmacokinetic profile of pacritinib creates both clinical convenience and a significant vulnerability. While its good oral bioavailability, long half-life, and lack of a food effect support a simple twice-daily dosing regimen, its near-exclusive reliance on the CYP3A4 metabolic pathway makes it highly susceptible to drug-drug interactions. This is a critical management consideration, as the target patient population—often elderly with multiple comorbidities—is frequently on polypharmacy.

• Strong CYP3A4 Inhibitors: Co-administration of pacritinib with strong inhibitors of CYP3A4 (e.g., clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice) is contraindicated.[1] These agents can significantly increase pacritinib plasma concentrations, elevating the risk of toxicity. A clinical study with clarithromycin demonstrated a 1.3-fold increase in pacritinib maximum concentration ( Cmax​) and a 1.8-fold increase in the area under the curve (AUC).[37]
• Strong CYP3A4 Inducers: Co-administration of pacritinib with strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) is also contraindicated.[1] These agents can dramatically decrease pacritinib plasma concentrations, leading to a loss of therapeutic effect. A study with rifampin resulted in a 51% reduction in pacritinib Cmax​ and a staggering 87% reduction in AUC, effectively rendering the drug subtherapeutic.[37]
• Other Interactions: Pacritinib may also decrease the effectiveness of hormonal contraceptives (with the exception of levonorgestrel-containing intrauterine systems), necessitating the use of alternative or additional contraceptive methods.[9]

Clinical Development and Efficacy in Myelofibrosis

Overview of the PERSIST Clinical Trial Program

The clinical efficacy of pacritinib was primarily evaluated in a program of two pivotal Phase 3 clinical trials, known as PERSIST-1 and PERSIST-2.[12] A defining and unique feature of this program was the deliberate inclusion of patients with pre-existing cytopenias, including those with severe thrombocytopenia (platelet counts

<50×109/L). This was a departure from the pivotal trials of other JAK inhibitors, which typically excluded such patients, and it positioned pacritinib to address a key unmet need.[12]

Deep Dive: The PERSIST-2 Trial Design

The PERSIST-2 trial was the cornerstone study that provided the primary evidence for pacritinib's FDA approval.

• Objective: The trial was designed as a randomized, controlled, multicenter study to compare the efficacy and safety of pacritinib against the Best Available Therapy (BAT) in patients with myelofibrosis and significant thrombocytopenia.[39]
• Patient Population: The study enrolled 311 patients with intermediate- or high-risk primary or secondary MF who had a baseline platelet count of ≤100×109/L.[10] The trial was notable for allowing enrollment of patients who had been previously treated with ruxolitinib; 48% of the study population had received prior ruxolitinib therapy.[12] The patient population was characterized by advanced disease, with a median baseline platelet count of 55×109/L, and 45-46% of patients having severe thrombocytopenia with counts below 50×109/L.[12]
• Randomization: Patients were randomized in a 1:1:1 ratio to one of three arms: pacritinib 400 mg once daily (QD), pacritinib 200 mg twice daily (BID), or BAT. The BAT arm was determined by the investigator and could include ruxolitinib, hydroxyurea, or watchful waiting.[10]
• Co-Primary Endpoints: The trial had two co-primary efficacy endpoints, both assessed at Week 24: (1) the proportion of patients achieving a spleen volume reduction (SVR) of ≥35% from baseline, as measured by MRI or CT scan, and (2) the proportion of patients achieving a reduction in Total Symptom Score (TSS) of ≥50% from baseline.[10]

Efficacy Outcomes from PERSIST-2

The efficacy results from PERSIST-2 were nuanced and pivotal to the drug's regulatory fate.

• Spleen Volume Reduction (SVR): The trial successfully met its co-primary endpoint for SVR. In the primary analysis, which pooled the two pacritinib arms, 18% of patients achieved a ≥35% SVR, compared to only 3% of patients in the BAT arm. This difference was statistically significant (p=0.001).[39]
• Total Symptom Score (TSS): In the primary analysis of the pooled pacritinib arms, the trial did not meet its co-primary endpoint for symptom reduction. While a higher proportion of pacritinib-treated patients achieved a ≥50% TSS reduction (25%) compared to the BAT arm (14%), the difference did not reach statistical significance (p=0.079).[39]

Efficacy in the Target Population and by Dose (The Basis for Approval)

The failure to meet one of the co-primary endpoints in the primary analysis could have jeopardized the drug's approval. However, pre-specified and subgroup analyses provided a clear and scientifically valid path forward, ultimately forming the basis of the FDA's decision.

• Subgroup Analysis (Platelets <50×109/L): In the specific patient population for which pacritinib is now approved, the 200 mg BID dose demonstrated a robust and clinically meaningful effect. The SVR rate was 29% for pacritinib versus just 3% for BAT.[10] Symptom reduction was also clearly superior in this high-need group, with 26% of pacritinib patients achieving the TSS endpoint versus 9% on BAT.[16]
• Dose-Specific Analysis (200 mg BID): When the FDA-approved 200 mg BID dose was analyzed as a distinct cohort against BAT, it demonstrated statistically significant superiority for both co-primary endpoints. This analysis was critical, as it identified a specific dose and regimen with a clear and comprehensive benefit.
• SVR ≥35%: 22% in the pacritinib 200 mg BID arm vs. 3% in the BAT arm (p=0.001).[39]
• TSS ≥50% reduction: 32% in the pacritinib 200 mg BID arm vs. 14% in the BAT arm (p=0.011).[39]
• Association with Survival: Further bolstering the evidence of clinical benefit, landmark analyses of the PERSIST-2 data demonstrated that achieving any level of SVR (e.g., ≥10%) while on pacritinib was associated with a significant improvement in overall survival (OS). This association was not observed for patients who achieved SVR while on BAT, suggesting that the disease modification conferred by pacritinib may offer a unique survival advantage in this patient population.[42]

The nuanced efficacy results of the PERSIST-2 trial are summarized in Table 5.1, highlighting the distinction between the pooled analysis and the dose-specific analysis that supported approval.

Table 5.1: Summary of Co-Primary Efficacy Endpoints from the PERSIST-2 Trial

Efficacy Endpoint (at Week 24)	Pooled Pacritinib Arms vs. BAT	Pacritinib 200 mg BID vs. BAT	Source(s)
Proportion with SVR ≥35%	18% vs. 3% (p=0.001)	22% vs. 3% (p=0.001)	39
Proportion with TSS Reduction ≥50%	25% vs. 14% (p=0.079)	32% vs. 14% (p=0.011)	39

Safety, Tolerability, and Risk Management

Common and Serious Adverse Events

The safety profile of pacritinib is characterized by frequent, generally manageable gastrointestinal and hematologic toxicities, alongside several serious risks that require careful monitoring.

• Most Common Adverse Events (AEs): In clinical trials, the most frequently reported AEs (occurring in ≥20% of patients) were diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema.[4] Diarrhea is particularly common but is typically low-grade and can be managed with supportive care.[9]
• Most Frequent Serious Adverse Events (SAEs): SAEs occurring in ≥3% of patients treated with pacritinib 200 mg BID included anemia (8%), thrombocytopenia (6%), pneumonia (6%), cardiac failure (4%), disease progression (3%), pyrexia (3%), and squamous cell carcinoma of the skin (3%).[10]
• Key Risks Highlighted in Warnings:
• Hemorrhage: The label carries a prominent warning for severe and sometimes fatal bleeding events. This risk was a key concern during clinical development.[9]
• QTc Prolongation: Pacritinib can prolong the cardiac QTc interval, which creates a risk for life-threatening arrhythmias like Torsades de Pointes. Patients may experience dizziness, lightheadedness, or fainting as a result.[9]

The FDA Clinical Hold and Its Resolution

The late-stage development of pacritinib was profoundly impacted by a major regulatory action based on emerging safety data.

• In February 2016, the FDA placed a full clinical hold on the entire pacritinib investigational program. This decision was prompted by an interim analysis of data from the PERSIST trials, which suggested an increased risk of death, intracranial hemorrhage, and cardiac failure in patients treated with pacritinib compared to those on BAT.[12]
• The initial data showed an increased mortality hazard ratio for pacritinib in both PERSIST-1 (HR 1.29) and PERSIST-2 (HR 1.29), raising significant safety alarms.[12]
• The clinical hold was ultimately lifted in early 2017, approximately one year later. The resolution came after the sponsor submitted the final, complete data from the trials and a revised study protocol. The final analyses provided a more nuanced picture of the safety profile. Specifically, it became evident that the 200 mg BID dose had a more favorable safety profile than the 400 mg QD dose, with a lower mortality rate and fewer cardiac events.[12] This dose-dependent safety profile was instrumental in reviving the program and ultimately defined the path to approval. The entire trajectory of pacritinib's development was dictated by these safety signals, which forced a refinement of the dose and a narrowing of the target indication to a population where the benefit-risk calculation was deemed favorable.

Class-Wide JAK Inhibitor Warnings

As a member of the JAK inhibitor class, pacritinib's labeling includes several important warnings that apply to other drugs in this category, based on data from large safety studies in other diseases like rheumatoid arthritis.

• Major Adverse Cardiovascular Events (MACE): An increased risk of heart attack, stroke, or cardiovascular death has been observed with other JAK inhibitors, particularly in patients who are current or past smokers or have other cardiovascular risk factors.[1]
• Thrombosis: An increased risk of blood clots in the veins of the legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE), as well as arterial thrombosis, is a known class effect.[1]
• Secondary Malignancies: There is a possible increased risk of developing new cancers, including lymphoma and non-melanoma skin cancer.[1]
• Serious Infections: JAK inhibitors can suppress the immune system, leading to an increased risk of serious bacterial, mycobacterial, fungal, and viral infections.[1]

Hepatotoxicity

In clinical trials, pacritinib therapy has been associated with transient and usually mild elevations in serum aminotransferase levels. However, to date, it has not been definitively linked to instances of clinically apparent acute liver injury. Its likelihood score for causing liver injury is categorized as E* (unproven, but a possible cause). As with other JAK inhibitors, there is a theoretical risk of reactivating hepatitis B.[4]

Regulatory Journey and Global Status

U.S. FDA Approval

The path to market for pacritinib in the United States was a testament to a flexible and need-driven regulatory process.

• Timeline: CTI BioPharma completed its rolling submission of a New Drug Application (NDA) in March 2021. Following a Priority Review, VONJO™ (pacritinib) received accelerated approval from the FDA on February 28, 2022.[11]
• Indication: The approval is highly specific and narrowly defined: for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50×109/L.[11]
• Basis for Approval: The accelerated approval was based on the spleen volume reduction (SVR) endpoint from the PERSIST-2 trial. The FDA concluded that SVR is a surrogate endpoint that is "reasonably likely to predict a clinical benefit".[9] This pathway was utilized because pacritinib addresses a serious condition and provides a therapeutic benefit over available therapies for a population with a significant unmet medical need, as there were no other FDA-approved treatments for this specific group.[13]
• Post-Marketing Requirement: As a condition of accelerated approval, continued approval for this indication is contingent upon the verification and description of clinical benefit in a confirmatory trial. The ongoing PACIFICA study is designed to fulfill this requirement.[13]

European Medicines Agency (EMA) Application Withdrawal

In sharp contrast to the outcome in the U.S., pacritinib failed to gain approval in Europe.

• Timeline: CTI BioPharma formally withdrew its European Marketing Authorization Application (MAA) for pacritinib (under the proposed brand name Enpaxiq) on two separate occasions, most notably in February 2017 and again in 2019.[18]
• Rationale: The withdrawals were made after the company received feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that the committee was likely to adopt a formal negative opinion on the application.[18]
• CHMP Concerns: The CHMP's assessment identified multiple significant deficiencies in the risk-benefit profile of pacritinib based on the data submitted from the PERSIST-1 trial [17]:
• Insufficient Efficacy: The committee concluded that the magnitude of spleen volume reduction appeared to be lower than that of another medicine in its class and noted a lack of demonstrated improvement in patient-reported symptom scores.
• Unfavorable Safety Profile: The CHMP highlighted a higher incidence of bleeding events (associated with low platelet counts) and, most critically, a higher number of deaths in the pacritinib arm compared to the BAT arm, including deaths due to bleeding and cardiac events.
• Data Gaps: The committee also requested more information regarding the manufacturing process and a more detailed elucidation of the drug's mechanism of action on its target proteins.

The divergent regulatory outcomes in the U.S. and Europe serve as a compelling case study in differing regulatory philosophies. The FDA utilized the accelerated approval pathway, a flexible mechanism designed to bring drugs for serious conditions with unmet needs to patients more quickly, accepting a surrogate endpoint and a complex safety profile with the safeguard of a required confirmatory trial. The EMA, in contrast, applied a more stringent and holistic risk-benefit assessment to the same data package and concluded that the benefits demonstrated did not outweigh the significant risks observed. This highlights that "approvability" is not an absolute measure but a context-dependent judgment that weighs clinical data against the specific public health needs and risk tolerance of a given regulatory jurisdiction.

Dosing, Administration, and Special Populations

Recommended Dosing

The recommended and FDA-approved dose of pacritinib is 200 mg taken orally twice daily.[1]

Method of Administration

For optimal delivery and safety, pacritinib should be administered according to the following instructions:

• The 100 mg capsules should be swallowed whole. They must not be opened, broken, or chewed.[1]
• The medication can be taken with or without food.[1]

Dose Modifications and Management

The dose of pacritinib may need to be adjusted during the course of treatment based on individual patient factors:

• Dose adjustments are recommended based on tolerability and routine blood test results, particularly platelet counts.[1]
• Dose modifications may also be necessary to manage potential drug-drug interactions, although co-administration with strong CYP3A4 inhibitors or inducers is contraindicated.[4]

Use in Special Populations

Specific recommendations and precautions apply to the use of pacritinib in certain patient populations:

• Hepatic Impairment: The use of pacritinib should be avoided in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to the lack of safety and pharmacokinetic data in this group.[10]
• Renal Impairment: The use of pacritinib should be avoided in patients with severe renal impairment, defined as an estimated Glomerular Filtration Rate (eGFR) of <30 mL/min.[10]
• Pregnancy and Lactation: Pacritinib may cause fetal harm when administered to a pregnant woman. It is not known whether the drug or its metabolites are excreted in human milk. Therefore, breastfeeding should be avoided during treatment and for two weeks after the final dose.[9]
• Fertility: Based on findings in animal studies, pacritinib may impair male fertility.[10]

Synthesis, Expert Opinion, and Future Directions

Concluding Synthesis

Pacritinib is a paradigm of modern targeted therapy, designed with a specific pharmacological rationale to address a molecularly defined disease. Its journey from development to market, however, illustrates that a clever pharmacological profile does not guarantee a straightforward path to approval. The drug's unique kinome selectivity, particularly its sparing of JAK1, provides a clear scientific basis for its clinical application in myelofibrosis patients with cytopenias, a population with a dire unmet need. Yet, its clinical development was a tumultuous process, defined by a precarious balance between demonstrated efficacy in this desperate population and significant safety concerns that prompted a full FDA clinical hold and rejection by European regulators. Through meticulous dose optimization and a regulatory process that ultimately prioritized the high unmet medical need, pacritinib successfully carved out a crucial, albeit narrow, clinical niche. It stands as an important therapeutic option, but also as a case study in the complexities of drug development, where safety, efficacy, and regulatory philosophy intersect to define a drug's ultimate place in medicine.

Expert Opinion and Placement in Therapy

In the current therapeutic landscape, pacritinib (VONJO™) is the undisputed standard of care and a first-line consideration for patients with intermediate- or high-risk myelofibrosis who present with severe thrombocytopenia (platelet count <50×109/L). For this specific patient population, it offers a proven benefit in spleen volume reduction where no other approved therapies exist. Conversely, it is not intended for, nor should it be used as a primary option in, myelofibrosis patients with adequate platelet counts (≥50×109/L). In that setting, ruxolitinib remains the established frontline standard of care due to its well-documented efficacy, including a proven overall survival benefit. The successful and safe use of pacritinib hinges on two critical principles: careful patient selection according to its precise indication, and vigilant, proactive management of its known toxicities and significant drug-drug interaction potential.

Future Directions

The future development and role of pacritinib will be shaped by several key factors:

• Confirmatory Trial: The most immediate and critical milestone is the successful completion and positive readout of the PACIFICA study. This confirmatory trial is essential to verify the clinical benefit of pacritinib and convert its accelerated approval into a full, unrestricted approval, thereby solidifying its long-term place in the treatment algorithm for myelofibrosis.
• Exploration in Other Malignancies: The potent dual inhibition of JAK2 and FLT3, along with its activity against other inflammatory kinases like IRAK1, provides a strong scientific rationale for investigating pacritinib in other hematologic malignancies. There is significant potential for its use in acute myeloid leukemia (AML) with FLT3 mutations, myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML). Clinical trials in these areas are either planned or already underway, which could substantially broaden the drug's utility.[18]
• Combination Therapies: Due to its manageable and distinct toxicity profile—most notably, its limited myelosuppression—pacritinib is an attractive candidate for use in combination regimens. Combining pacritinib with other novel agents in myelofibrosis could potentially lead to deeper, more durable responses and further improve patient outcomes. Its tolerability makes it a logical backbone for such investigational strategies.[36]

Works cited

1. Pacritinib (oral route) - Side effects & dosage - Mayo Clinic, accessed August 20, 2025, https://www.mayoclinic.org/drugs-supplements/pacritinib-oral-route/description/drg-20530927
2. Pacritinib | SB1518 | CAS#937272-79-2 | JAK2 inhibitor | MedKoo Biosciences, accessed August 20, 2025, https://www.medkoo.com/products/5719
3. Profile of pacritinib and its potential in the treatment of hematologic disorders - PMC, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4145824/
4. Pacritinib - LiverTox - NCBI Bookshelf, accessed August 20, 2025, https://www.ncbi.nlm.nih.gov/books/NBK601409/
5. go.drugbank.com, accessed August 20, 2025, https://go.drugbank.com/drugs/DB11697#:~:text=Pacritinib%20is%20thought%20to%20exert,tyrosine%20kinase%203%20(FLT3).&text=It%20has%20a%20greater%20inhibitory,JAK1%20at%20clinically%20relevant%20concentrations.
6. Pacritinib - Wikipedia, accessed August 20, 2025, https://en.wikipedia.org/wiki/Pacritinib
7. en.wikipedia.org, accessed August 20, 2025, https://en.wikipedia.org/wiki/Pacritinib#:~:text=Pacritinib%2C%20sold%20under%20the%20brand,medication%20used%20to%20treat%20myelofibrosis.
8. Pacritinib | C28H32N4O3 | CID 46216796 - PubChem, accessed August 20, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Pacritinib
9. Vonjo for Myelofibrosis Treatment | VONJO® (pacritinib), accessed August 20, 2025, https://www.vonjo.com/
10. VONJO® (pacritinib) HCP: VONJO® for Myelofibrosis Treatment, accessed August 20, 2025, https://www.vonjohcp.com/
11. VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High, accessed August 20, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2022/vonjo-fda-approved-treatment-intermediate-high-risk-myelofibrosis/
12. Pacritinib (VONJO) in Myelofibrosis National Drug Monograph May 2023 | VA.gov, accessed August 20, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/MON_Pacritinib_VONJO_in_Myelofibrosis_Monograph_May_2023.pdf
13. 208712Orig1s000 INTEGRATED REVIEW - accessdata.fda.gov, accessed August 20, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/208712Orig1s000IntegratedR.pdf
14. Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis - Targeted Oncology, accessed August 20, 2025, https://www.targetedonc.com/view/pacritinib-shows-transfusion-independence-benefits-in-myelofibrosis
15. Pacritinib: First Approval - PubMed, accessed August 20, 2025, https://pubmed.ncbi.nlm.nih.gov/35567653/
16. VONJO® PERSIST-2 Trial Design, accessed August 20, 2025, https://www.vonjohcp.com/persist-2-trial-study-design
17. Company again withdraws application for pacritinib | MDedge - The Hospitalist, accessed August 20, 2025, https://community.the-hospitalist.org/content/company-again-withdraws-application-pacritinib
18. CTI BioPharma Withdraws EMA Application for Pacritinib | American Pharmaceutical Review, accessed August 20, 2025, https://www.americanpharmaceuticalreview.com/1315-News/358073-CTI-BioPharma-Withdraws-EMA-Application-for-Pacritinib/
19. Enpaxiq | European Medicines Agency (EMA), accessed August 20, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/enpaxiq
20. Pacritinib (SB1518, CAS Number: 937272-79-2) - Cayman Chemical, accessed August 20, 2025, https://www.caymanchem.com/product/16709/pacritinib
21. Pacritinib (SB1518)|JAK2/FLT3 inhibitor - APExBIO, accessed August 20, 2025, https://www.apexbt.com/pacritinib-sb1518.html
22. pacritinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 20, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793
23. Pacritinib - KEGG DRUG, accessed August 20, 2025, https://www.kegg.jp/entry/D11768
24. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active ..., accessed August 20, 2025, https://pubmed.ncbi.nlm.nih.gov/25600203/
25. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia - PMC, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6439520/
26. Compound: PACRITINIB (CHEMBL2035187) - ChEMBL - EMBL-EBI, accessed August 20, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2035187
27. Pacritinib | CAS 937272-79-2 | Cayman Chemical | Biomol.com, accessed August 20, 2025, https://www.biomol.com/products/chemicals/biochemicals/pacritinib-cay16709-500
28. Pacritinib (SB1518) supplier | CAS 937272-79-2 |JAK2 inhibitor | AOBIOUS, accessed August 20, 2025, https://aobious.com/aobious/kinase-inhibitors/1729-pacritinib-sb1518.html
29. Pacritinib (SB1518) | JAK2/FLT3 Inhibitor | MedChemExpress, accessed August 20, 2025, https://www.medchemexpress.com/pacritinib.html
30. Pacritinib: MedlinePlus Drug Information, accessed August 20, 2025, https://medlineplus.gov/druginfo/meds/a622043.html
31. medlineplus.gov, accessed August 20, 2025, https://medlineplus.gov/druginfo/meds/a622043.html#:~:text=Pacritinib%20is%20in%20a%20class,signals%20cancer%20cells%20to%20multiply.
32. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans | Request PDF - ResearchGate, accessed August 20, 2025, https://www.researchgate.net/publication/271334464_Metabolism_and_Disposition_of_Pacritinib_SB1518_an_Orally_Active_Janus_Kinase_2_Inhibitor_in_Preclinical_Species_and_Humans
33. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor | Reaction Biology, accessed August 20, 2025, https://www.reactionbiology.com/wp-content/uploads/2023/11/Comprehensive-Kinase-Profile-of-Pacritinib-a-nonmyelosuppressive-Janus-Kinase-2-Inhibitor.pdf
34. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3256753/
35. Pacritinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 20, 2025, https://go.drugbank.com/drugs/DB11697
36. Pacritinib: a new agent for the management of myelofibrosis? - PubMed, accessed August 20, 2025, https://pubmed.ncbi.nlm.nih.gov/26389774/
37. Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor | Blood, accessed August 20, 2025, https://ashpublications.org/blood/article/126/23/5178/94684/Clinical-Pharmacology-Profile-of-Pacritinib-PAC-a
38. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia | Haematologica, accessed August 20, 2025, https://haematologica.org/article/view/haematol.2021.279415
39. PERSIST-2: Pacritinib Compared With Best Available Therapy for Patients With Myelofibrosis and Thrombocytopenia | ASH Clinical News | American Society of Hematology, accessed August 20, 2025, https://ashpublications.org/ashclinicalnews/news/1896/PERSIST-2-Pacritinib-Compared-With-Best-Available
40. CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis - PR Newswire, accessed August 20, 2025, https://www.prnewswire.com/news-releases/cti-biopharma-announces-top-line-results-from-persist-2-phase-3-trial-of-pacritinib-for-high-risk-patients-with-advanced-myelofibrosis-300319128.html
41. Final Results From PERSIST-2: Pacritinib Superior to Best Available Therapy in Patients With Myelofibrosis and Thrombocytopenia | ASH Clinical News | American Society of Hematology, accessed August 20, 2025, https://ashpublications.org/ashclinicalnews/news/3850/Final-Results-From-PERSIST-2-Pacritinib-Superior
42. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival - PMC, accessed August 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11707811/
43. Vonjo (pacritinib) FDA Approval History - Drugs.com, accessed August 20, 2025, https://www.drugs.com/history/vonjo.html
44. CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update - BioSpace, accessed August 20, 2025, https://www.biospace.com/cti-biopharma-receives-results-of-the-chmp-oral-explanation-for-pacritinib-in-the-treatment-of-myelofibrosis-and-provides-development-update
45. Pacritinib Not Yet Recruiting Phase 1 Trials for Myelodysplastic Syndrome Treatment, accessed August 20, 2025, https://go.drugbank.com/drugs/DB11697/clinical_trials?conditions=DBCOND0028333&phase=1&purpose=treatment&status=not_yet_recruiting
46. Pacritinib Completed Phase 2 Trials for Mantle Cell Lymphoma (MCL) / Hodgkin's Lymphoma / Indolent Lymphoma Treatment | DrugBank Online, accessed August 20, 2025, https://go.drugbank.com/drugs/DB11697/clinical_trials?conditions=DBCOND0030382%2CDBCOND0040598%2CDBCOND0071979&phase=2&purpose=treatment&status=completed
47. Pacritinib Bests Available Therapies for Myelofibrosis | Cancer Discovery - AACR Journals, accessed August 20, 2025, https://aacrjournals.org/cancerdiscovery/article/5/7/OF7/5157/Pacritinib-Bests-Available-Therapies-for